New botanical drug, HL tablet, reduces hepatic fat as measured by magnetic resonance spectroscopy in patients with nonalcoholic fatty liver disease: A placebo-controlled, randomized, phase II trial

doi:10.3748/wjg.v23.i32.5977

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 32

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7195)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

518

WORD

216

HTML

3600

Figures (1-2)

191

Tables (1-4)

144

Sum=4669

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1015

Download

1511

Sum=2526

Aug 28, 2017 (publication date) through Apr 23, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Controlled Trial

World J Gastroenterol. Aug 28, 2017; 23(32): 5977-5985
Published online Aug 28, 2017. doi: 10.3748/wjg.v23.i32.5977

Open in New Tab Full Size Figure Download Figure

Figure 1 Flow chart of the study participants.

Open in New Tab Full Size Figure Download Figure

Figure 2 Changes of hepatic fat content from baseline after 12 wk of treatment.

Citation: Jeong JY, Sohn JH, Baek YH, Cho YK, Kim Y, Kim H. New botanical drug, HL tablet, reduces hepatic fat as measured by magnetic resonance spectroscopy in patients with nonalcoholic fatty liver disease: A placebo-controlled, randomized, phase II trial. World J Gastroenterol 2017; 23(32): 5977-5985
URL: https://www.wjgnet.com/1007-9327/full/v23/i32/5977.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i32.5977